您的当前位置:首页 > 行业数据 > 度普利尤单抗与乌帕替尼、阿布西替尼安全性数据对比
图片属性
图片格式:PNG 图片大小:130KB 图片尺寸:2324*618
同报告图片
 / 4
度普利尤单抗与乌帕替尼、阿布西替尼安全性数据对比_第1页
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
度普利尤单抗与乌帕替尼、阿布西替尼安全性数据对比_第2页
度普利尤单抗与乌帕替尼、阿布西替尼安全性数据对比_第3页
度普利尤单抗与乌帕替尼、阿布西替尼安全性数据对比_第4页
度普利尤单抗与乌帕替尼、阿布西替尼安全性数据对比_第5页
所属报告: 智翔金泰-公司研究报告:赛立奇单抗放量可期创新管线迈入收获期-241203(37页).pdf
打包全文图表

相关数据

客服
商务合作
小程序
服务号
折叠